Matthew Tucker

Alabama Oncology (Grandview Cancer Center). Previously @VUMCHemOnc, @IMresidencyDuke. Views expressed here are my own.

[Matthew Tucker @Tucker_MatthewD]

Our paper on the baseline neutrophil-to-eosinophil ratio and response to nivo/ipi in patients with mRCC is out now! @VUMC_Cancer, @VUMCHemOnc, @DukeCancer, @DukeGuCancer #kidneycancer, #biomarkers https://t.co/imRJTcZxFR 1/8

[Matthew Tucker @Tucker_MatthewD]

@andyzwang @TiansterZhang @utswcancer Congratulations @TiansterZhang ! Awesome news!

[Brian Rini, MD @brian_rini]

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD

[Matthew Tucker @Tucker_MatthewD]

@EricLanderMD @CathyEngMD @mgibson21212 @VUMCHemOnc @NateraOncology Congratulations!!

[Yu-Wei Chen, MD, MS @YuWeiChenMD]

Please stop by our biomarker-driven OPTIC RCC Trial-in-Progress Poster (TPS 742) lead by @brian_rini @DrScottHaake @katy_beckermann, Anupama Reddy ,Yu Shyr @KimrynRathmell @montypal @TiansterZhang @MosheOrnsteinMD @PBarataMD, Natalia Mar @Uromigos @ASCO #GU23

[Cancer Cell @Cancer_Cell]

T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer? https://t.co/r2xL0KBe4s

[Myriam Chalabi @MyriamChalabi]

In a month’s time, we’ve learned that CD8 T cells aren’t the only effectors of immunotherapy response: stealing the show: eosinophils @Cancer_Cell and γδ T cells @Nature out today! @NKI_nl @lab_kok @deVisserKarin @deMirandaLab https://t.co/Vy32yfG3iU https://t.co/xr2uniJpGj

[MarleenKokLab @lab_kok]

1/ Happy to share👇(Tweetorial) our work on T-cell eosinophil crosstalk during immunotherapy response in breast cancer now online @Cancer_Cell A major team-effort lead by Blomberg, Spagnuolo, @hannah_c_garner, @LVoorwerk w/co-senior @deVisserKarin @NKI_nl https://t.co/5ndzMR929u

[Matthew Tucker @Tucker_MatthewD]

@drlauragoff Incredible!! Thanks for posting. I was wondering if baby yoda could be topped!

[Brian Rini, MD @brian_rini]

Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.

[Uromigos @Uromigos]

We’re having an interactive uromigos meeting in Nashville 30 Sept-1st Oct @DrRanaMcKay @MattGalsky @neerajaiims @DrRosenbergMSK @Prof_Nick_James @montypal @TiansterZhang @shilpaonc @PGrivasMDPhD @Daniel_J_George @kalasri3 details in the podcast https://t.co/SVeV5Kr3Rf…

[Matthew Tucker @Tucker_MatthewD]

So proud of my co-fellow @YuWeiChenMD ! Merit Award, YIA, and three posters at #ASCO22 ! Look out Kidney cancer, Dr. Chen is on the scene! @VUMC_Cancer

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

A busy poster session in the GU section! Congrats to #YuWeiChen #MattTucker @LandonBrownMD for this poster on NER ratio trends on ipi-nivo in metastatic #kidneycancer. #ASCO22

[Matthew Tucker @Tucker_MatthewD]

@esinghimd @MDAndersonNews @MDanmolsingh @MadhuEluri Congratulations to you both!!!!

[Brian Rini, MD @brian_rini]

New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to @DrChoueiri and Mike Atkins for help assembling data.

[Stephen V Liu, MD @StephenVLiu]

Can artificial intelligence predict outcomes with immunotherapy in NSCLC? Report @JCO_ASCO on an #AI powered spatial analysis of tumor infiltrating lymphocytes (TIL) on whole slide images to define immune phenotypes that correlate to RR and survival.

https://t.co/EVmIpm0kPE

[Chris Cann, MD @ChrisCannMD]

Thanks @oncologytube for the opportunity to discuss the potential role of #ctdna within #SCLC. Shout out to @WadeIams for all his guidance and advocacy for the use of ctdna to guide treatment and improve pt outcomes

[Dr. jordan berlin @jordanberlin5]

Been slow to do this. Congratulations to @VUMCHemOnc @VUMC_Cancer renal team on getting two new Department of Defense Grants to improve our biomarker analyses of renal cell cancer/therapy. @brian_rini @DrScottHaake @KimrynRathmell @katy_beckermann @YuWeiChenMD and Yu Shyr

[Yu-Wei Chen, MD, MS @YuWeiChenMD]

Dr. Jaime Merchan discusses matching sequencing data with available therapies in RCC and highlights the OPTIC RCC trial lead by Dr. Brian Rini @brian_rini @VUMCHemOnc @VUMC_Cancer @ASCO #GU22

[Yu-Wei Chen, MD, MS @YuWeiChenMD]

Dr. Sam Chang @UroCancerMD presents the exciting combination of IL-15 agonist (N-803) and BCG in BCG-unresponsive NMIBC @VUMC_Cancer @VUMCurology @ASCO #GU22

[Brian Rini, MD @brian_rini]

Adjuvant Pembrolizumab After Nephrectomy in Renal Cell Carcinoma: Embracing the Promises and Acknowledging the Uncertainties. #ASCODailyNews @ASCO https://t.co/pNXG2yFuu1

[Matthew Tucker @Tucker_MatthewD]

@DukeIMChiefs @IMResidencyDuke @MattLabsMD @Duke_SEEDS Combining a renal mass and the coagulation cascade in one chalk-talk. What a pro @MattLabsMD